glycine has been researched along with Acute Lymphoid Leukemia in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pemetrexed represents the first antifolate cancer drug to be approved by the Food and Drug Administration in 20 years; it is currently in widespread use for first line therapy of mesothelioma and non-small cell lung cancer." | 3.75 | Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. ( Heyer, CL; Moran, RG; Racanelli, AC; Rothbart, SB, 2009) |
| "Acute lymphoblastic leukemia (ALL) is a disease of lymphoid progenitor cells with an often aggressive course and is commonly caused by the BCR-ABL fusion gene t(9;22) in adults." | 1.72 | Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia. ( Appelmann, I; Brümmendorf, TH; Koschmieder, S; Maletzke, S; Masouleh, BK; Salimi, A; Schemionek, M; Schroeder, KM; Vieri, M, 2022) |
| "Ixazomib (IXA) is an orally available proteasome inhibitor, with an improved safety profile compared to Bortezomib (BTZ)." | 1.62 | Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. ( Cloos, J; Jansen, G; Kaspers, GJL; Kwidama, ZJ; Roeten, MSF; Segerink, WH; Ter Huizen, G; van Meerloo, J; Zweegman, S, 2021) |
| "We propose that patients whose tumors show this phenotype will be sensitive to folate antagonists targeting thymidylate or purine biosynthesis." | 1.39 | Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors. ( Bertino, JR; Tedeschi, PM; Vazquez, A, 2013) |
| "We studied 170 patients with acute lymphoblastic leukemia (ALL), treated from 1988 to 1994 according to a protocol derived from BFM-83 studies, in order to evaluate the incidence and prognostic significance of mutations in this gene in childhood ALL." | 1.31 | Lack of association between N-ras gene mutations and clinical prognosis in Brazilian children with acute lymphoblastic leukemia. ( Clementino, NC; Costa, FF; Figueiredo, MS; Kerbauy, J; Saad, ST; Viana, MB; Yamamoto, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Amrein, P | 1 |
| Ballen, K | 1 |
| Stevenson, K | 1 |
| Brunner, A | 1 |
| Hobbs, G | 1 |
| Hock, H | 1 |
| McAfee, S | 1 |
| Moran, J | 1 |
| Bergeron, M | 1 |
| Foster, J | 1 |
| Bertoli, C | 1 |
| McGreggor, K | 1 |
| Macrea, M | 1 |
| Burke, M | 1 |
| Behnam, T | 1 |
| Som, T | 1 |
| Ramos, A | 1 |
| Vartanian, M | 1 |
| Lombardi Story, J | 1 |
| Connolly, C | 1 |
| Blonquist, T | 1 |
| Neuberg, D | 1 |
| Fathi, A | 1 |
| Maletzke, S | 1 |
| Salimi, A | 1 |
| Vieri, M | 1 |
| Schroeder, KM | 1 |
| Schemionek, M | 1 |
| Masouleh, BK | 1 |
| Brümmendorf, TH | 1 |
| Koschmieder, S | 1 |
| Appelmann, I | 1 |
| Roeten, MSF | 1 |
| van Meerloo, J | 1 |
| Kwidama, ZJ | 1 |
| Ter Huizen, G | 1 |
| Segerink, WH | 1 |
| Zweegman, S | 1 |
| Kaspers, GJL | 1 |
| Jansen, G | 1 |
| Cloos, J | 1 |
| Racanelli, AC | 1 |
| Rothbart, SB | 1 |
| Heyer, CL | 1 |
| Moran, RG | 1 |
| Ganguly, A | 1 |
| Basu, S | 1 |
| Banerjee, K | 1 |
| Chakraborty, P | 1 |
| Sarkar, A | 1 |
| Chatterjee, M | 1 |
| Chaudhuri, SK | 1 |
| Oussenko, IA | 1 |
| Holland, JF | 1 |
| Reddy, EP | 1 |
| Ohnuma, T | 1 |
| Vazquez, A | 1 |
| Tedeschi, PM | 1 |
| Bertino, JR | 1 |
| Clementino, NC | 1 |
| Yamamoto, M | 1 |
| Viana, MB | 1 |
| Figueiredo, MS | 1 |
| Kerbauy, J | 1 |
| Saad, ST | 1 |
| Costa, FF | 1 |
8 other studies available for glycine and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Glycine; Humans; Precursor Ce | 2022 |
Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Boron Compounds; Bortezomib; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr | 2022 |
Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Topics: Boron Compounds; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycine; Humans; Leukemia, | 2021 |
Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.
Topics: Adenylate Kinase; Aminoimidazole Carboxamide; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; | 2009 |
Redox active copper chelate overcomes multidrug resistance in T-lymphoblastic leukemia cell by triggering apoptosis.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Cell Cycle; Cell Line; Cell Line | 2011 |
Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation.
Topics: Camptothecin; Cell Cycle; Cell Line, Tumor; DNA Damage; Doxorubicin; Glycine; GTPase-Activating Prot | 2011 |
Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors.
Topics: Biological Transport; Folic Acid; Folic Acid Antagonists; Glycine; Humans; Methotrexate; Mitochondri | 2013 |
Lack of association between N-ras gene mutations and clinical prognosis in Brazilian children with acute lymphoblastic leukemia.
Topics: Amino Acid Substitution; Base Sequence; Bone Marrow Cells; Brazil; Child; Child, Preschool; Cloning, | 2001 |